Resistance to ocular antibiotics: An overview

Clinical and Experimental Optometry

Volumn 90, Issue 4, 2007, Pages 258-262

  Brown, Lindsay ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Aminoglycosides; Antibiotics; Bacterial resistance; Chloramphenicol; Fluoroquinolones

Indexed keywords

ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL EYE INFECTION; BACTERIAL PHENOMENA AND FUNCTIONS; DRUG RESISTANCE; HUMAN; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIAL PHYSIOLOGY; DRUG RESISTANCE; EYE INFECTIONS, BACTERIAL; HUMANS;

EID: 34547354966     PISSN: 08164622     EISSN: 14440938     Source Type: Journal    
DOI: 10.1111/j.1444-0938.2007.00154.x     Document Type: Article

References (31)

1. AIHW 2005. Mortality over the twentieth century in Australia: Trends and patterns in major causes of death. Mortality Surveillance Series no. 4. AIHW cat. no. PHE73. Canberra, Australia: Australian Institute of Health and Welfare, 2005.
2. http://nobelprize.org/nobel_prizes/nobelprize_facts.html
3. Petri WA Jr. Antimicrobial agents (continued). Penicillins, cephalosporins and other β-lactam antibiotics. In : Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. New York, NY : McGraw-Hill Companies, Inc, 2001. p 1189 1218.
4. Salyers AA, Whitt DD. Revenge of the microbes: how bacterial resistance is undermining the antibiotic miracle. Washington DC : ASM Press, 2005.
5. Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dale's Pharmacology, 6th ed. Edinburgh : Churchill Livingstone Elsevier, 2007. p 647 678.
6. Rice LB. Antimicrobial resistance in gram-positive bacteria. Am J Infect Control 2006 34 : S11 S19.
7. Gould IM. Costs of hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) and its control. Int J Antimicrob Agents 2006 28 : 379 384.
8. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Med 2006 119 : S3 S10.
9. Hawkey PM. The origins and molecular basis of antibiotic resistance. BMJ 1998 317 : 657 660.
10. Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature 2000 406 : 775 781.
11. Choi S-H, Woo JH, Lee JE, Park SJ, Choo EJ, Kwak YG, Kim M-N, Choi M-S, Lee NY, Lee BK, Kim NJ, Jeong J-Y, Ryu J, Kim YS. Increasing incidence of quinolone resistance in human non-typhoid Salmonella enterica isolates in Korea and mechanisms involved in quinolone resistance. J Antimicrob Chemother 2005 56 : 1111 1114.
12. Srinivasan VB, Virk RK, Kaundal A, Chakraborty R, Datta B, Ramamurthy T, Mukhopadhyay AK, Bhosh A. Mechanism of drug resistance in clonally related clinical isolates of Vibrio fluvalis isolated in Kolkata, India. Antimicrob Agents Chemother 2006 50 : 2428 2432.
13. Ge B, McDermott PF, White DG, Meng J. Role of efflux pumps and topoisomerase mutations in fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother 2005 49 : 3347 3354.
14. Saito R, Sato K, Kumita W, Inami N, Nishiyama H, Okamura N, Moriya K, Koike K. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis. J Antimicrob Chemother 2006 58 : 673 677.
15. Cirz RT, Romesberg FE. Induction and inhibition of ciprofloxacin resistance-conferring mutations in hypermutator bacteria. Antimicrob Agents Chemother 2006 50 : 220 225.
16. Jana S, Deb JK. Molecular targets for design of novel inhibitors to circumvent aminoglycoside resistance. Current Drug Targets 2005 6 : 353 361.
17. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis. Ophthalmology 1999 206 : 1313 1318.
18. Tuft SJ, Matheson M. In vitro antibiotic resistance in bacterial keratitis in London. Br J Ophthalmol 2000 84 : 687 691.
19. Chalita MR, Höfling-Lima AL, Paranhos A Jr., Schor P, Belfort R. Shifting trends in in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 years. Am J Ophthalmol 2004 137 : 43 51.
20. Morrissey I, Burnett R, Viljoen L, Robbins M. Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001-2002. J Infection 2004 49 : 109 114.
21. Marangon FB, Miller D, Muallem MS, Romano AC, Alfonso EC. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am J Ophthalmol 2004 137 : 453 458.
22. Kotlus BS, Wymbs RA, Vellozzi EM, Udell IJ. In vitro activity of fluoroquinolones, vancomycin, and gentamicin against methicillin-resistant Staphylococcus aureus ocular isolates. Am J Ophthalmol 2006 142 : 726 729.
23. Shanmuganathan VA, Armstrong M, Bulkler A, Tullo AB. External ocular infections due to methicillin-resistant Staphylococcus aureus (MRSA). Eye 2005 19 : 284 291.
24. Fukuda M, Ohashi H, Matsumoto C, Mishima S, Shimomura Y. Methicillin-resistant Staphylococcus aureus and methicillin-resistant coagulase-negative Staphylococcus ocular surface infection efficacy of chloramphenicol eye drops. Cornea 2002 21 (Suppl S86 S89.
25. Kodsi S. Community-acquired methicillin-resistant Staphylococcus aureus in association with chronic dacryocystitis secondary to congenital nasolacrimal duct obstruction. J AAPOS 2006 10 : 583 584.
26. Leeming JP. Treatment of ocular infections with topical antibacterials. Clin Pharmacokinet 1999 37 : 351 360.
27. Frishman WH, Kowalski M, Nagnar S, Warshafsky S, Sica D. Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension. Focus on β-adrenergic blockade. Heart Disease 2001 3 : 386 397.
28. Antibiotic Guidelines version 13, 2006, Therapeutic Guidelines Limited, Ground Floor, 23-47 Villiers Street, North Melbourne, Victoria 3051, Australia (http://www.tg.com.au).
29. Schlossberg D. Clinical approach to antibiotic failure. Med Clin N Am 2006 90 : 1265 1277.
30. Vicente M, Hodgson J, Massidda O, Tonjum T, Henriques-Normark B, Ron EZ. The fallacies of hope: will we discover new antibiotics to combat pathogenic bacteria in time? FEMS Microbiol Rev 2006 30 : 841 852.
31. Bradley JS, Guidos R, Baragona S, Bartlett JG, Rubinstein E, Zhanel GG, Tino MD, Pompliano DL, Tally F, Tipirneni P, Tillotson GS, Powers JH, Tillotson GS. Anti-infective research and development-problems, challenges and solutions. Lancet Infect Dis 2007 7 : 68 78.